EIF4G2

Across TCGA pan-cancer cohorts, EIF4G2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF4G2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF4G2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF4G2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where EIF4G2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.689	0.902	.002	73	view →
CCRCC	DFS	Tertile	IV	0.174	0.961	.024	15	view →
HNSC	DFS	Median	IV	0.791	0.525	.008	13	view →
GBM	OS	Tertile	All	0.244	0.472	.011	10	view →
LSCC	DFS	Median	All	0.831	0.576	.006	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF4G2–PDAC (DFS)

Open the PDAC breakdown →